Jonathan Gardner
Senior Reporter | @ByJonGardner
857 articles by Jonathan Gardner
-
AbbVie tries to reassure investors on Humira biosimilar threat
April 26, 2024 -
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
April 25, 2024 -
Eisai hunts for next Alzheimer’s drug with new research pact
April 22, 2024 -
Alvotech deal could heighten biosimilar pressure on Humira
April 19, 2024 -
Lilly obesity drug shows benefit in sleep disorder study, pointing to new use
April 17, 2024 -
Roche reports survival data for new dual-acting lymphoma drug
April 15, 2024 -
European regulator concludes no suicide link to obesity drugs
April 12, 2024 -
Novartis pauses enrollment in some Kisqali trials to fix manufacturing
April 10, 2024 -
Trial shows Wegovy can ease heart failure symptoms
April 8, 2024 -
Bristol Myers says KRAS drug succeeds in key trial
March 29, 2024 -
FDA approves Akebia anemia pill, two years after rejection
March 28, 2024 -
FDA approves Merck lung disease drug acquired in $11B deal
March 26, 2024 -
Viking stays in obesity drug race with early data for weight loss pill
March 26, 2024 -
FDA rejects Regeneron lymphoma drug, setting back company’s oncology push
March 25, 2024 -
Roche autoimmune disease drug disappoints in closely watched trial
March 21, 2024 -
FDA panel backs broader use of J&J, Bristol Myers cell therapies for myeloma
March 15, 2024 -
BIO changes stance, backs bill to limit China’s role in US biotech
March 14, 2024 -
FDA to focus on ‘early deaths’ in meeting on broader CAR-T use in myeloma
March 13, 2024 -
Roche, following setbacks, turns to its next Alzheimer’s drug
March 11, 2024 -
FDA delays decision on Lilly’s closely watched Alzheimer’s drug
March 8, 2024 -
Novo’s latest obesity pill spurs major weight loss in small trial
March 7, 2024 -
Alnylam, Roche blood pressure drug scores in second mid-stage trial
March 5, 2024 -
AstraZeneca’s drug pricing lawsuit dismissed by federal judge
March 4, 2024 -
Pfizer, looking for a jumpstart, leans into cancer drug research
March 1, 2024 -
Viking data suggest obesity drug could rival Zepbound, Wegovy
Feb. 27, 2024